NSRX — Nasus Pharma Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.72 | ||
| Price to Tang. Book | 3.72 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -91.7% | ||
| Return on Equity | -316.04% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nasus Pharma Ltd. is an Israel-based pharmaceutical company. The Company develops and manufactures pharmaceutical products and intranasal powder-based drug delivery systems. Its proprietary microsphere technology is designed to enable non-invasive intranasal administration of medications for emergency and acute-care applications, including the treatment of anaphylaxis and opioid overdose. The Company's formulations are designed to support rapid drug absorption and administration without the use of injections. Nasus Pharma Ltd. focuses on the development of drug delivery solutions intended for use by healthcare professionals, caregivers, first responders, and other non-professional users. The Company's products aim to improve the accessibility and administration of critical medications in emergency situations.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- May 13th, 2019
- Public Since
- August 13th, 2025
- No. of Shareholders
- 95
- No. of Employees
- 7
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 11,713,808
- Address
- Yigal Alon 65, TEL AVIV, 6473925
- Web
- https://www.nasuspharma.com
- Phone
- +972 37326616
- Auditors
- Brightman Almagor Zohar & Co
Latest News for NSRX
Similar to NSRX
Can Fite Biopharma
NYSE MKT
cbdMD
NYSE MKT
China Pharma Holdings
NYSE MKT
Pelthos Therapeutics
NYSE MKT
Protalix BioTherapeutics
NYSE MKT
FAQ
As of Today at 22:14 UTC, shares in Nasus Pharma are trading at $3.49. This share price information is delayed by 15 minutes.
Shares in Nasus Pharma last closed at $3.49 and the price had moved by -54.08% over the past 365 days. In terms of relative price strength the Nasus Pharma share price has underperformed the S&P500 Index by -59.09% over the past year.
The overall consensus recommendation for Nasus Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreNasus Pharma does not currently pay a dividend.
Nasus Pharma does not currently pay a dividend.
Nasus Pharma does not currently pay a dividend.
To buy shares in Nasus Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.49, shares in Nasus Pharma had a market capitalisation of $40.88m.
Here are the trading details for Nasus Pharma:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: NSRX
Based on an overall assessment of its quality, value and momentum Nasus Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Nasus Pharma is $18.50. That is 430.09% above the last closing price of $3.49.
Analysts covering Nasus Pharma currently have a consensus Earnings Per Share (EPS) forecast of -$1.13 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nasus Pharma. Over the past six months, its share price has underperformed the S&P500 Index by -8.77%.
As of the last closing price of $3.49, shares in Nasus Pharma were trading -7.04% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Nasus Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.49.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Nasus Pharma's directors